Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has received clearance for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA), for F18-Pivalate…
Speaking on the sidelines of the Rule Symposium, Brent Cook, founder of Exploration Insights, shared his thoughts on the…
Given that inflation remains an issue for miners, he’s focusing on small gold royalty companies. ‘That’s what I’ve been…
A report published by S&P Global Market Intelligence reveals that the US lags significantly behind other countries in mine…
Dana Samuelson of American Gold Exchange discussed his outlook for gold and silver prices in both the short and…
GTI Energy Ltd (GTI or Company) is pleased to provide an update on the upcoming resource expansion drilling program…
The S&P/TSX Venture Composite Index (INDEXTSI:JX) lost 15.98 points last week to close at 580.09. Meanwhile, the S&P/TSX Composite…
CleanTech Lithium PLC (AIM:CTL, Frankfurt:T2N, OTCQX:CTLHF), an exploration and development company advancing sustainable lithium projects in Chile, announces completion…
The gold price remains historically high, but for Rich Checkan, president and CEO of Asset Strategies International, the yellow…